Why Is LIQUIDIA CORP (LQDA) Stock Up Today?

Liquidia Corp (LQDA) shares rose 7.37% to $51.40 on Wednesday. The primary driver was the company's third-quarter financial results, which showed a 31% sequential increase in YUTREPIA sales to $222.7 million, alongside the resolution of a legal dispute with United Therapeutics.

What Happened

Liquidia reported adjusted earnings per share of $1.71, significantly exceeding the consensus estimate of $0.96. Total sales came in at $250.0 million, beating the projected $214.182 million. The earnings call highlighted record October shipments and a widening prescriber base. The company also settled its litigation with United Therapeutics, removing a key overhang that had weighed on the stock.

Analysts responded positively to the results. Needham raised its price target to $66 from $58. BTIG maintained its Buy rating and increased its price target to $87.00. The broader market reaction was supported by strong fundamental metrics, including a trailing twelve-month revenue growth rate of 2,233.6% and a net margin of 30.7%.

What The Data Shows

The stock has gained 14.1% over the last eight sessions, moving from $45.06 to $51.40. Liquidia currently trades at a market capitalization of $4.0 billion with a P/E ratio of 32.4. The 52-week range stands between $22.31 and $93.61. On November 10, 2026, the stock printed 20 fresh 52-week highs and 4 fresh 52-week lows.

Insider activity has been predominantly selling. In the last 90 days, there were 17 sales totaling $25.8 million, with no recorded buys. The most recent filings on October 26, 2026, involved sales by Chief Accounting Officer Dana Boyle and Chief Business Officer Jason Adair. Congressional trading data shows three sales and one buy in the same period, with the most recent filing dated October 8, 2026.

What To Watch

Investors will monitor coverage breadth following the recent price target upgrades. The company is scheduled to present at the 2026 Jefferies Global Healthcare Conference.